MYMK: A Potential Drug Target for Cancer and Other Diseases (G389827)

Target Name: MYMK

NCBI ID: G389827

MYMK

MYMK: A Potential Drug Target for Cancer and Other Diseases

MYMK (MYMK-HUMAN) is a protein that is expressed in human tissues and has been identified as a potential drug target for various diseases, including cancer.MYMK is a member of the superfamily of FERMTases, which are a group of enzymes that are involved in cell division and have been implicated in a variety of diseases, including cancer.

One of the unique features of MYMK is its ability to interact with several different proteins, including the protein known as p53. This interaction between MYMK and p53 has been shown to play a role in the regulation of cell division and the development of cancer.

In addition to its role in cell division, MYMK has also been shown to be involved in the regulation of cell growth and the signaling of cell-cell interactions. This involvement in cell growth and cell-cell interactions has been implicated in the development of various diseases, including cancer.

Another unique feature of MYMK is its ability to interact with the protein known as NF-kappa-B. This interaction between MYMK and NF-kappa-B has been shown to play a role in the regulation of inflammation and the development of certain diseases.

In addition to its role in cell division, MYMK has also been shown to be involved in the regulation of cell death. This involvement in cell death has been implicated in the development of various diseases, including cancer.

MYMK has also been shown to interact with the protein known as T-cell receptor 4 (TCR4). This interaction between MYMK and TCR4 has been shown to play a role in the regulation of immune responses and the development of certain diseases.

In conclusion, MYMK is a protein that has been shown to interact with several different proteins, including p53, NF-kappa-B, and TCR4. These interactions have been implicated in the regulation of various diseases, including cancer. As a potential drug target, MYMK is a promising target for the development of new treatments for a variety of diseases.

Protein Name: Myomaker, Myoblast Fusion Factor

Functions: Myoblast-specific protein that mediates myoblast fusion, an essential step for the formation of multi-nucleated muscle fibers (PubMed:28681861). Actively participates in the membrane fusion reaction by mediating the mixing of cell membrane lipids (hemifusion) upstream of MYMX. Acts independently of MYMX (By similarity). Involved in skeletal muscle regeneration in response to injury by mediating the fusion of satellite cells, a population of muscle stem cells, with injured myofibers (By similarity). Also involved in skeletal muscle hypertrophy, probably by mediating the fusion of satellite cells with myofibers (By similarity)

The "MYMK Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MYMK comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets